|School||University of California, San Diego|
|Address||9500 Gilman Drive #0820|
CA La Jolla 92093
Dr. Jamieson specialized in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies. In the past two years, Dr. Jamieson’s stem-cell research studies have taken a great leap: from identifying a promising treatment in the laboratory to opening and completing the first clinical trial to target cancer stem cells in humans. This trial is the result of teamwork that has brought together her discoveries in myeloproliferative neoplasms and a local pharmaceutical company’s drug development track.
Education and Training
BS - Biology-Genetics, University of British Columbia - 1987
Ph.D. - Microbiology, University of British Columbia - 1992
MD - University of British Columbia - 1995
Resident - University of British Columbia - 1995-1998
Fellow, Bone Marrow Transplant - University of British Columbia - 1998
Fellow, Bone Marrow Transplant - Stanford University - 1999-2002
Postdoctoral Research Fellow - Stanford University - 2002-2005
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share similar concepts with this person.